Talphera (NASDAQ:TLPH) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Talphera (NASDAQ:TLPH) to a hold rating in a report published on Monday morning,Zacks.com reports.

TLPH has been the topic of a number of other research reports. Westpark Capital assumed coverage on Talphera in a report on Thursday, April 30th. They issued a “buy” rating and a $3.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a report on Monday, April 20th. Finally, HC Wainwright initiated coverage on Talphera in a report on Friday, June 5th. They set a “buy” rating and a $3.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Talphera currently has an average rating of “Hold” and a consensus target price of $3.00.

Talphera Price Performance

TLPH opened at $0.82 on Monday. The stock has a market cap of $42.33 million, a P/E ratio of -2.63 and a beta of 0.76. The stock’s 50 day simple moving average is $0.81 and its 200 day simple moving average is $0.94. Talphera has a 1-year low of $0.38 and a 1-year high of $1.57.

Talphera (NASDAQ:TLPH) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. Research analysts expect that Talphera will post -0.26 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Vincent J. Angotti bought 213,310 shares of the stock in a transaction on Friday, March 13th. The shares were purchased at an average price of $0.59 per share, for a total transaction of $125,852.90. Following the acquisition, the chief executive officer owned 800,705 shares in the company, valued at $472,415.95. This represents a 36.31% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On Talphera

A number of large investors have recently bought and sold shares of the stock. Group One Trading LLC grew its holdings in Talphera by 3,224.0% during the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after buying an additional 29,500 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Talphera during the third quarter worth $29,000. Mariner LLC boosted its holdings in shares of Talphera by 132.0% during the fourth quarter. Mariner LLC now owns 58,000 shares of the company’s stock worth $66,000 after purchasing an additional 33,000 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Talphera during the fourth quarter worth $42,000. Finally, Dauntless Investment Group LLC acquired a new stake in shares of Talphera during the third quarter worth $89,000. Institutional investors and hedge funds own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.